These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 22336832

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA, Odelola OA, Saldanha IJ.
    Cochrane Database Syst Rev; 2014 May 22; (5):CD007743. PubMed ID: 24851825
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
    Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV.
    Cochrane Database Syst Rev; 2021 Nov 16; 11(11):CD013757. PubMed ID: 34783356
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC.
    Pediatr Crit Care Med; 2011 Sep 16; 12(5):580-8. PubMed ID: 21200358
    [Abstract] [Full Text] [Related]

  • 12. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP, Lee SWH.
    Pharmacotherapy; 2017 Jun 16; 37(6):755-769. PubMed ID: 28423192
    [Abstract] [Full Text] [Related]

  • 13. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.
    Buchs C, Dalphin ML, Sanchez S, Perceval M, Coutier L, Mainguy C, Kassaï-Koupaï B, Reix P.
    Eur J Pediatr; 2017 Jul 16; 176(7):891-897. PubMed ID: 28508992
    [Abstract] [Full Text] [Related]

  • 14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 16; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 15. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2018 Jun 16; 37(6):1113-1118. PubMed ID: 29557081
    [Abstract] [Full Text] [Related]

  • 16. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
    Health Technol Assess; 2008 Dec 16; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [Abstract] [Full Text] [Related]

  • 17. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.
    Pediatr Pulmonol; 2008 Feb 16; 43(2):169-74. PubMed ID: 18085710
    [Abstract] [Full Text] [Related]

  • 18. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C, Scott LJ, Plosker GL.
    Paediatr Drugs; 2004 Feb 16; 6(3):177-97. PubMed ID: 15170364
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 16; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 20. Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis.
    Sánchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L.
    Allergol Immunopathol (Madr); 2015 Dec 16; 43(3):298-303. PubMed ID: 24231153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.